Article info
PDFSpecial populations
Original research
Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease
- Correspondence to Dr Darryl Leong, Population Health Research Institute, McMaster University, Hamilton, ON L8L 2X2, Canada; leongd{at}phri.ca
Citation
Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease
Publication history
- Received September 12, 2020
- Revised December 3, 2020
- Accepted December 7, 2020
- First published January 8, 2021.
Online issue publication
January 08, 2022
Article Versions
- Previous version (8 January 2022).
- Previous version (8 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.